Haleon is due to report its first-quarter earnings on 1 May with UBS upping its organic sales growth forecast to 3.2% from 3.0% previously.
Comparatives are tough in Respiratory Health and Pain Relief but these will be offset by expected continued strong momentum in Oral Health, said the bank.
For 2024, UBS expects Haleon to achieve 5.0% organic sales growth and +80bps organic operating margin expansion, resulting in a top quartile operating profit growth of 9%.
Barclays is forecasting organic sales growth for the year of 4.9%.